NEW YORK (GenomeWeb News) – CombiMatrix has been warned by Nasdaq that it doesn't meet a requirement to remain being listed on the exchange, the Irvine, Calif.-based firm said after the close of the market on Friday.

CombiMatrix said that it received a notification dated June 26 from the Listing Qualifications department of Nasdaq telling the company that it was in violation of a listing requirement calling for a minimum bid of $1 per share, "based upon the closing bid price for the last 30 consecutive business days."

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A Thomson Reuters analysis indicates that the life sciences, rather than the tech sector, are increasingly driving global innovation.

The White House says ethical discussions about genome editing of the human germline are needed.

In Genome Research this week: mitochondrial and nuclear gene fusions in cancer, role of genomic imprinting in tissue-specific gene expression, and more.

Maria Freire from the Foundation for the NIH calls for "politically popular pledges of support" for the NIH to turn into support for increased funding for the agency.